174 related articles for article (PubMed ID: 35315319)
1. Presence of mutant p53 increases stem cell frequency and is associated with reduced binding to classic TP53 binding sites in cell lines and primary AMLs.
Gerritsen M; Hilgendorf S; Yi G; Wierenga ATJ; Schuringa JJ; Martens JHA; Vellenga E
Exp Hematol; 2022 Jun; 110():39-46. PubMed ID: 35315319
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of autophagy as a treatment strategy for p53 wild-type acute myeloid leukemia.
Folkerts H; Hilgendorf S; Wierenga ATJ; Jaques J; Mulder AB; Coffer PJ; Schuringa JJ; Vellenga E
Cell Death Dis; 2017 Jul; 8(7):e2927. PubMed ID: 28703806
[TBL] [Abstract][Full Text] [Related]
3. Role of p53 in regulation of hematopoiesis in health and disease.
Barajas S; Cai W; Liu Y
Curr Opin Hematol; 2022 Jul; 29(4):194-200. PubMed ID: 35787548
[TBL] [Abstract][Full Text] [Related]
4. AML chemoresistance: The role of mutant TP53 subclonal expansion and therapy strategy.
Yan B; Claxton D; Huang S; Qiu Y
Exp Hematol; 2020 Jul; 87():13-19. PubMed ID: 32569759
[TBL] [Abstract][Full Text] [Related]
5. Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells.
Carter BZ; Mak PY; Muftuoglu M; Tao W; Ke B; Pei J; Bedoy AD; Ostermann LB; Nishida Y; Isgandarova S; Sobieski M; Nguyen N; Powell RT; Martinez-Moczygemba M; Stephan C; Basyal M; Pemmaraju N; Boettcher S; Ebert BL; Shpall EJ; Wallner B; Morgan RA; Karras GI; Moll UM; Andreeff M
Blood; 2023 Sep; 142(12):1056-1070. PubMed ID: 37339579
[TBL] [Abstract][Full Text] [Related]
6. Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia.
Becker H; Pfeifer D; Ihorst G; Pantic M; Wehrle J; Rüter BH; Bullinger L; Hackanson B; Germing U; Kuendgen A; Platzbecker U; Döhner K; Ganser A; Hagemeijer A; Wijermans PW; Döhner H; Duyster J; Lübbert M
Ann Hematol; 2020 Jul; 99(7):1551-1560. PubMed ID: 32504186
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of sPRDM16 coupled with loss of p53 induces myeloid leukemias in mice.
Shing DC; Trubia M; Marchesi F; Radaelli E; Belloni E; Tapinassi C; Scanziani E; Mecucci C; Crescenzi B; Lahortiga I; Odero MD; Zardo G; Gruszka A; Minucci S; Di Fiore PP; Pelicci PG
J Clin Invest; 2007 Dec; 117(12):3696-707. PubMed ID: 18037989
[TBL] [Abstract][Full Text] [Related]
8. Activating STING1-dependent immune signaling in
Kogan AA; Topper MJ; Dellomo AJ; Stojanovic L; McLaughlin LJ; Creed TM; Eberly CL; Kingsbury TJ; Baer MR; Kessler MD; Baylin SB; Rassool FV
Proc Natl Acad Sci U S A; 2022 Jul; 119(27):e2123227119. PubMed ID: 35759659
[TBL] [Abstract][Full Text] [Related]
9. Modeling the Etiology of p53-mutated Cancer Cells.
Perez RE; Shen H; Duan L; Kim RH; Kim T; Park NH; Maki CG
J Biol Chem; 2016 May; 291(19):10131-47. PubMed ID: 27022024
[TBL] [Abstract][Full Text] [Related]
10. A gain-of-function p53 mutant synergizes with oncogenic NRAS to promote acute myeloid leukemia in mice.
Rajagopalan A; Feng Y; Gayatri MB; Ranheim EA; Klungness T; Matson DR; Lee MH; Jung MM; Zhou Y; Gao X; Nadiminti KV; Yang DT; Tran VL; Padron E; Miyamoto S; Bresnick EH; Zhang J
J Clin Invest; 2023 Dec; 133(24):. PubMed ID: 37847561
[TBL] [Abstract][Full Text] [Related]
11. Human pluripotent stem cells recurrently acquire and expand dominant negative P53 mutations.
Merkle FT; Ghosh S; Kamitaki N; Mitchell J; Avior Y; Mello C; Kashin S; Mekhoubad S; Ilic D; Charlton M; Saphier G; Handsaker RE; Genovese G; Bar S; Benvenisty N; McCarroll SA; Eggan K
Nature; 2017 May; 545(7653):229-233. PubMed ID: 28445466
[TBL] [Abstract][Full Text] [Related]
12. p53 involvement in clonal hematopoiesis of indeterminate potential.
Chen S; Liu Y
Curr Opin Hematol; 2019 Jul; 26(4):235-240. PubMed ID: 31045645
[TBL] [Abstract][Full Text] [Related]
13. The role of TP53 in acute myeloid leukemia: Challenges and opportunities.
Barbosa K; Li S; Adams PD; Deshpande AJ
Genes Chromosomes Cancer; 2019 Dec; 58(12):875-888. PubMed ID: 31393631
[TBL] [Abstract][Full Text] [Related]
14. A Gain-of-Function p53-Mutant Oncogene Promotes Cell Fate Plasticity and Myeloid Leukemia through the Pluripotency Factor FOXH1.
Loizou E; Banito A; Livshits G; Ho YJ; Koche RP; Sánchez-Rivera FJ; Mayle A; Chen CC; Kinalis S; Bagger FO; Kastenhuber ER; Durham BH; Lowe SW
Cancer Discov; 2019 Jul; 9(7):962-979. PubMed ID: 31068365
[TBL] [Abstract][Full Text] [Related]
15. Interpretative differences of combined cytogenetic and molecular profiling highlights differences between MRC and ELN classifications of AML.
Sussman RT; Manning B; Ackerman D; Bigdeli A; Pammer P; Velu PD; Luger SM; Bagg A; Carroll M; Morrissette JJD
Cancer Genet; 2021 Aug; 256-257():68-76. PubMed ID: 33915454
[TBL] [Abstract][Full Text] [Related]
16. A high prevalence of myeloid malignancies in progeria with Werner syndrome is associated with p53 insufficiency.
Kato H; Maezawa Y; Nishijima D; Iwamoto E; Takeda J; Kanamori T; Yamaga M; Mishina T; Takeda Y; Izumi S; Hino Y; Nishi H; Ishiko J; Takeuchi M; Kaneko H; Koshizaka M; Mimura N; Kuzuya M; Sakaida E; Takemoto M; Shiraishi Y; Miyano S; Ogawa S; Iwama A; Sanada M; Yokote K
Exp Hematol; 2022 May; 109():11-17. PubMed ID: 35240258
[TBL] [Abstract][Full Text] [Related]
17. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia.
Wong TN; Ramsingh G; Young AL; Miller CA; Touma W; Welch JS; Lamprecht TL; Shen D; Hundal J; Fulton RS; Heath S; Baty JD; Klco JM; Ding L; Mardis ER; Westervelt P; DiPersio JF; Walter MJ; Graubert TA; Ley TJ; Druley T; Link DC; Wilson RK
Nature; 2015 Feb; 518(7540):552-555. PubMed ID: 25487151
[TBL] [Abstract][Full Text] [Related]
18. Novel high-risk acute myeloid leukemia subgroup with ERG amplification and Biallelic loss of TP53.
Schandl CA; Mazzoni S; Znoyko I; Nahhas GJ; Chung D; Ding Y; Hess B; Wolff DJ
Cancer Genet; 2023 Apr; 272-273():23-28. PubMed ID: 36657266
[TBL] [Abstract][Full Text] [Related]
19. TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia.
Tashakori M; Kadia T; Loghavi S; Daver N; Kanagal-Shamanna R; Pierce S; Sui D; Wei P; Khodakarami F; Tang Z; Routbort M; Bivins CA; Jabbour EJ; Medeiros LJ; Bhalla K; Kantarjian HM; Ravandi F; Khoury JD
Blood; 2022 Jul; 140(1):58-72. PubMed ID: 35390143
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic targeting of TP53-mutated acute myeloid leukemia by inhibiting HIF-1α with echinomycin.
Wang Y; Liu Y; Bailey C; Zhang H; He M; Sun D; Zhang P; Parkin B; Baer MR; Zheng P; Malek SN; Liu Y
Oncogene; 2020 Apr; 39(14):3015-3027. PubMed ID: 32060420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
